PRINCETON, N.J., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (SONN) (the "Company" or "Sonnet"), a clinical-stage company developing immunotherapeutic drugs targeted to the ...
Sonnet BioTherapeutics Holdings, Inc. announced that its abstract has been accepted for a poster presentation at the 2025 American Association for Cancer Research (AACR) IO Conference, scheduled for ...
- Raghu Rao, Interim Chief Executive Officer and Dr. Richard Kenney, Chief Medical Officer, of Sonnet discuss the recently announced safety data related to SON-1010 This press release contains certain ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback